PT - JOURNAL ARTICLE AU - Ilja Demuth AU - Verena L. Banszerus AU - Johanna Drewelies AU - Sandra Düzel AU - Ute Seeland AU - Dominik Spira AU - Esther Tse AU - Julian Braun AU - Lars Bertram AU - Andreas Thiel AU - Ulman Lindenberger AU - Vera Regitz-Zagrosek AU - Denis Gerstorf AU - Additional BASE-II/GendAge investigators TI - Cohort Profile Update: GendAge and Berlin Aging Study II (BASE-II) AID - 10.1101/2020.09.05.20187898 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.05.20187898 4099 - http://medrxiv.org/content/early/2020/09/07/2020.09.05.20187898.short 4100 - http://medrxiv.org/content/early/2020/09/07/2020.09.05.20187898.full AB - The study “Sex- and gender-sensitive prevention of cardiovascular and metabolic disease in older adults in Germany”, the GendAge study, focusses on major risk factors for cardiovascular and metabolic diseases and on the development of major outcomes from intermediate phenotypes in the context of biological sex and gender differences. It is based on a re-investigation of participants of the Berlin Aging Study II (BASE-II). The Berlin Aging Study II (BASE-II) is aiming at identifying factors that distinguish healthy from unhealthy ageing and completed baseline assessments in 2,200 adult volunteers (1,600 participants aged 60–80 years and 600 participants aged 20–35 years) in 2014. The BASE-II follow-up assessments of 1,100 men and women aged 65–94 years in 2018–2020 were part of GendAge. In addition to re-assessing most baseline measures (geriatrics, internal medicine, immunology and psychology) we implemented a comprehensive gender questionnaire covering socio-cultural gender characteristics and added high-quality echocardiography.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00016157Funding StatementThe GendAge study research project (Co-PIs are Ilja Demuth, Vera Regitz-Zagrosek, and Denis Gerstorf) is supported by the German Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung, BMBF) grant numbers 01GL1716A (ID and VRZ) and 01GL1716B (DG). Genomics assessments are funded by the Cure Alzheimers Fund (as part of the CIRCUITS-AD consortium project) and the European Research Councils Horizon2020 funding scheme (as part of the Lifebrain consortium project; both to LB). Additional contributions (e.g., equipment, logistics, personnel) are made from each of the participating sites.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The GendAge study was approved by the Ethics Committee of the Charite-Universitaetsmedizin Berlin (approval number EA2/144/16) and all participants gave written informed consent. GendAge is registered in the German Clinical Trials Register (Study-ID: DRKS00016157). The cognitive battery was approved by the Ethics Committee of the Max-Planck-Institute and the genomics experiments were approved by the Ethics Committees of the Charite (approval number EA2/144/16) and the University of Luebeck (approval numbers AZ19-390A and 19-391A).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMore details on GendAge can be found at https://gendage.charite.de/en/ and information on the BASE-II as a whole is available at https://www.base2.mpg.de/en. BASE-II has a tradition of sharing data and biobank samples in joint collaborative projects which will be continued with respect to BASE-II data assessed in GendAge. Interested groups are invited to contact the study coordinating PI Ilja Demuth at ilja.demuth{at}charite.de for the data-sharing application form. Each application will be reviewed by the GendAge PIs (currently ID, VRZ and DG) and the decision communicated to the applicants usually within 4 weeks of submission.